华润双鹤子公司阿法骨化醇软胶囊获得药品注册证书

Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. has received a drug registration certificate for Alfacalcidol soft capsules from the National Medical Products Administration, indicating a significant advancement in its product portfolio [1] Company Summary - The company's wholly-owned subsidiary, Beijing Wanhui Double Crane Pharmaceutical Co., Ltd., is responsible for the registration of Alfacalcidol soft capsules [1] - Alfacalcidol is indicated for the treatment of calcium metabolism disorders caused by insufficient endogenous 1,25-dihydroxyvitamin D3 production, which includes various conditions such as renal osteodystrophy and vitamin D-dependent rickets [1] Industry Summary - The approval of Alfacalcidol soft capsules highlights the growing demand for treatments addressing calcium metabolism disorders in the pharmaceutical industry [1] - The product is positioned to cater to a range of diseases, including osteoporosis and malabsorption-related conditions, reflecting the industry's focus on specialized therapeutic areas [1]